U.S. markets closed
  • S&P Futures

    4,460.00
    +14.25 (+0.32%)
     
  • Dow Futures

    34,814.00
    +140.00 (+0.40%)
     
  • Nasdaq Futures

    15,355.75
    +37.00 (+0.24%)
     
  • Russell 2000 Futures

    2,255.20
    +11.20 (+0.50%)
     
  • Crude Oil

    74.81
    +0.83 (+1.12%)
     
  • Gold

    1,752.70
    +1.00 (+0.06%)
     
  • Silver

    22.46
    +0.03 (+0.16%)
     
  • EUR/USD

    1.1725
    +0.0007 (+0.06%)
     
  • 10-Yr Bond

    1.4600
    +0.0500 (+3.55%)
     
  • Vix

    17.75
    -0.88 (-4.72%)
     
  • GBP/USD

    1.3672
    -0.0009 (-0.06%)
     
  • USD/JPY

    110.6920
    +0.0070 (+0.01%)
     
  • BTC-USD

    43,224.16
    +607.51 (+1.43%)
     
  • CMC Crypto 200

    1,075.91
    -27.15 (-2.46%)
     
  • FTSE 100

    7,051.48
    -26.87 (-0.38%)
     
  • Nikkei 225

    30,321.50
    +72.69 (+0.24%)
     

What Type Of Shareholders Make Up LogicBio Therapeutics, Inc.'s (NASDAQ:LOGC) Share Registry?

  • Oops!
    Something went wrong.
    Please try again later.
·4 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

Every investor in LogicBio Therapeutics, Inc. (NASDAQ:LOGC) should be aware of the most powerful shareholder groups. Institutions often own shares in more established companies, while it's not unusual to see insiders own a fair bit of smaller companies. Companies that used to be publicly owned tend to have lower insider ownership.

LogicBio Therapeutics is a smaller company with a market capitalization of US$124m, so it may still be flying under the radar of many institutional investors. Our analysis of the ownership of the company, below, shows that institutions are noticeable on the share registry. Let's take a closer look to see what the different types of shareholders can tell us about LogicBio Therapeutics.

Check out our latest analysis for LogicBio Therapeutics

ownership-breakdown
ownership-breakdown

What Does The Institutional Ownership Tell Us About LogicBio Therapeutics?

Institutions typically measure themselves against a benchmark when reporting to their own investors, so they often become more enthusiastic about a stock once it's included in a major index. We would expect most companies to have some institutions on the register, especially if they are growing.

As you can see, institutional investors have a fair amount of stake in LogicBio Therapeutics. This suggests some credibility amongst professional investors. But we can't rely on that fact alone since institutions make bad investments sometimes, just like everyone does. If multiple institutions change their view on a stock at the same time, you could see the share price drop fast. It's therefore worth looking at LogicBio Therapeutics' earnings history below. Of course, the future is what really matters.

earnings-and-revenue-growth
earnings-and-revenue-growth

We note that hedge funds don't have a meaningful investment in LogicBio Therapeutics. The company's largest shareholder is OrbiMed Advisors LLC, with ownership of 26%. Meanwhile, the second and third largest shareholders, hold 7.4% and 5.6%, of the shares outstanding, respectively. Furthermore, CEO Frederic Chereau is the owner of 0.8% of the company's shares.

We did some more digging and found that 6 of the top shareholders account for roughly 53% of the register, implying that along with larger shareholders, there are a few smaller shareholders, thereby balancing out each others interests somewhat.

While it makes sense to study institutional ownership data for a company, it also makes sense to study analyst sentiments to know which way the wind is blowing. There are plenty of analysts covering the stock, so it might be worth seeing what they are forecasting, too.

Insider Ownership Of LogicBio Therapeutics

The definition of company insiders can be subjective and does vary between jurisdictions. Our data reflects individual insiders, capturing board members at the very least. Company management run the business, but the CEO will answer to the board, even if he or she is a member of it.

Most consider insider ownership a positive because it can indicate the board is well aligned with other shareholders. However, on some occasions too much power is concentrated within this group.

I can report that insiders do own shares in LogicBio Therapeutics, Inc.. In their own names, insiders own US$4.2m worth of stock in the US$124m company. This shows at least some alignment, but I usually like to see larger insider holdings. You can click here to see if those insiders have been buying or selling.

General Public Ownership

The general public holds a 24% stake in LogicBio Therapeutics. While this group can't necessarily call the shots, it can certainly have a real influence on how the company is run.

Private Equity Ownership

With an ownership of 39%, private equity firms are in a position to play a role in shaping corporate strategy with a focus on value creation. Some investors might be encouraged by this, since private equity are sometimes able to encourage strategies that help the market see the value in the company. Alternatively, those holders might be exiting the investment after taking it public.

Next Steps:

While it is well worth considering the different groups that own a company, there are other factors that are even more important. Consider for instance, the ever-present spectre of investment risk. We've identified 4 warning signs with LogicBio Therapeutics , and understanding them should be part of your investment process.

Ultimately the future is most important. You can access this free report on analyst forecasts for the company.

NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures.

This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.